Australia - English - Department of Health (Therapeutic Goods Administration)

baxter laboratories pty ltd - zinc oxide, quantity: 215 mg/g - lotion - excipient ingredients: geranium oil; glyceryl isostearate; purified water; terminalia ferdinandiana; phenethyl alcohol; caprylyl glycol; potassium sorbate; citric acid; polyhydroxystearic acid; triethoxycaprylylsilane; medium chain triglycerides; glycerol; camellia sinensis; xanthan gum; cucumis sativus; safflower oil; isoamyl laurate; cetearyl glucoside; cetostearyl alcohol; sucrose cocoate; sorbitan monostearate; hydroxypropyl distarch phosphate

Kenya - English - Pharmacy and Poisons Board

pharmasell limited p.o. box 74158-00200 - heparin sodium - injection - 5000 iu/ml - heparin

Kenya - English - Pharmacy and Poisons Board

pharmasell limited p.o. box 74158-00200, kenya - nph human insulin (rdna origin) - suspension for injection - 100 iu/ml - insulin (human)

New Zealand - English - Medsafe (Medicines Safety Authority)

max health limited - acetylcysteine 20%{relative} - concentrate for infusion - 20% w/v - active: acetylcysteine 20%{relative} excipient: disodium edetate sodium hydroxide - n-acetylcysteine is indicated for the treatment of paracetamol overdose in patients: · who present within 15 hours after an acute overdose with a plasma paracetamol level on or above a line joining points of 150mg/l at 4h and 20mg/l at 15h (see nomogram below) or · who have taken more than 200mg/kg or 10g (whichever is less) of sustained release paracetamol or have one of two serum paracetamol levels taken four hours apart on or above a line joining points of 150mg/l at 4h and 20mg/l at 15h (see nomogram below) or · who have taken an acute overdose of paracetamol with opiates or medicines with anticholinergic effects and have one of two serum paracetamol levels taken four hours apart on or above a line joining points of 150mg/l at 4h and 20mg/l at 15h (see nomogram below) or · where there is any doubt over the time of an acute overdose, irrespective of plasma paracetamol level or · who present more than 15 hours after an overdose with abnormal liver biochemistry (inr >1.3 and/or alt>150) or fulminant hepatic failure or · who have taken a staggered overdose irrespective of plasma paracetamol level. staggered is defined as an overdose of 200mg/kg or 10g (whichever is less) over a single 24 hour period or 150mg/kg of 6g (whichever is less) per 24 hour period for at least 48 hours.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - acetylcysteine 200 mg/ml - concentrate for injection - 2 g/10ml - active: acetylcysteine 200 mg/ml excipient: disodium edetate dihydrate sodium hydroxide 5 m: 14.557 - 43.671 mg/ml sodium hydroxide water for injection - n-acetylcysteine is indicated for the treatment of paracetamol overdose in patients: - who present within 8 hours after an acute overdose of immediate-release paracetamol, with a serum paracetamol level on or over the nomogram line, or - who present more than 8 hours after an acute overdose of immediate-release paracetamol, or - who have ingested >= 200 milligrams/kg or >= 10 g (whichever is less) of modified-release paracetamol, or - who have ingested < 200 milligrams/kg and < 10 g of modified-release paracetamol, with serum paracetamol level over the nomogram line, or - who have ingested >= 200 milligrams/kg or >=10 g (whichever is less) of paracetamol over a single 24 hour period, and have an alt >=50 u/l or serum paracetamol concentration >=20 milligrams/l (132 micromol/l), or - who have ingested >=300 milligrams/kg or >=12 g (whichever is less) of paracetamol over a single 48 hour period, and have an alt >=50 u/l or serum paracetamol concentration >=20 milligrams/l (132 micromol/l), or - who have ingested the equivalent or more of a daily therapeutic dose of paracetamol per day for more than 48 hours and also have abdominal pain or nausea or vomiting, and have an alt >=50 u/l or serum paracetamol concentration >=20 milligrams/l (132 micromol/l), or - where there is any doubt over the time of an acute overdose, irrespective of serum paracetamol level, or - where serum paracetamol concentration is >=150 milligrams/l 4 hours post-ingestion in children less than 6 years of age.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - propafenone hydrochloride 150mg;  ;  ; propafenone hydrochloride 150mg - tablet - 150 mg - active: propafenone hydrochloride 150mg     excipient: croscarmellose sodium hypromellose   macrogol 400 macrogol 6000 magnesium stearate maize starch microcrystalline cellulose purified water titanium dioxide active: propafenone hydrochloride 150mg excipient: croscarmellose sodium hypromellose   macrogol 400 macrogol 6000 magnesium stearate microcrystalline cellulose pregelatinised maize starch purified water titanium dioxide - for the treatment of supraventricular extrasystoles and supraventricular tachycardias, and in wolff-parkinson-white (wpw) syndrome. also for the treatment of life-threatening documented ventricular tachyarrhythmia. the use of rytmonorm is not recommended in patients with less severe ventricular arrhythmias, even if the patients are symptomatic. because of the proarrhythimic effects of rytmonorm, its use should be reserved for patients in whom, in the opinion of the physician, the potential benefits of treatment outweigh the risks.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - propafenone hydrochloride 300mg - tablet - 300 mg - active: propafenone hydrochloride 300mg excipient: croscarmellose sodium hypromellose   macrogol 400 macrogol 6000 magnesium stearate maize starch microcrystalline cellulose purified water titanium dioxide - for the prophylaxis and treatment of supraventricular extrasystoles and supraventricular tachycardias, and in wpw syndrome. also for the prophylaxis and treatment of life-threatening documented ventricular arrhythmias, such as sustained ventricular tachycardia. the use of rytmonorm is not recommended in patients with less severe ventricular arrhythmias, even if the patients are symptomatic. because of the proarrhythimic effects of rytmonorm, its use should be reserved for patients in whom, in the opinion of the physician, the potential benefits of treatment outweigh the risks.

United States - English - NLM (National Library of Medicine)

azur pharma, inc. - doconexent (unii: zad9okh9jc) (doconexent - unii:zad9okh9jc) - doconexent 250 mg

European Union - English - EMA (European Medicines Agency)

tigenix n.v. - characterised viable autologous cartilage cells expanded ex vivo expressing specific marker proteins - cartilage diseases - other drugs for disorders of the musculo-skeletal system - repair of single symptomatic cartilage defects of the femoral condyle of the knee (international cartilage repair society [icrs] grade iii or iv) in adults.concomitant asymptomatic cartilage lesions (icrs grade i or ii) might be present. demonstration of efficacy is based on a randomised controlled trial evaluating the efficacy of chondrocelect in patients with lesions between 1 and 5 cm².

European Union - English - EMA (European Medicines Agency)

dendreon uk ltd - autologous peripheral-blood mononuclear cells including a minimum of 50 million autologous cd54+ cells activated with prostatic acid phosphatase granulocyte-macrophage colony-stimulating factor - prostatic neoplasms - other immunostimulants - provenge is indicated for treatment of asymptomatic or minimally symptomatic metastatic (non-visceral) castrate-resistant prostate cancer in male adults in whom chemotherapy is not yet clinically indicated.